Tech Company Financing Transactions
Apogee Therapeutics Funding Round
Blackstone invested in a $1.3 billion funding round for Apogee Therapeutics. The round was announced on 5/27/2026.
Transaction Overview
Company Name
Announced On
5/27/2026
Transaction Type
Debt
Amount
$1,300,000,000
Round
Undisclosed
Investors
Proceeds Purpose
This collaboration provides non-dilutive flexible funding at an attractive cost of capital for the late-stage development of zumilokibart and establishes a path to commercialization and profitability for Apogee.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
San Francisco, CA Undisclosed
USA
San Francisco, CA Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Overview
Apogee Therapeutics, Inc. is a biotechnology company advancing novel therapies to address patients' needs. Based in San Francisco and backed by leading life sciences funds, the company expects its lead pipeline program to enter clinical trials in 2023.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Henderson
Browse more venture capital transactions:
Prev: 5/27/2026: iFAST Diagnostics venture capital transaction
Next: 5/27/2026: Patron Points venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. All VC database entries on this site come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs